Cancer Biology & Medicine最新文献_第9页

Targeting the mechano-microenvironment and liver cancer stem cells: a promising therapeutic strategy for liver cancer. 靶向机械微环境和肝癌干细胞:一种有前景的肝癌治疗策略。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2023-11-24 DOI: 10.20892/j.issn.2095-3941.2023.0229

Xiaorong Fu, Yi Zhang, Qing Luo, Yang Ju, Guanbin Song

{"title":"Targeting the mechano-microenvironment and liver cancer stem cells: a promising therapeutic strategy for liver cancer.","authors":"Xiaorong Fu, Yi Zhang, Qing Luo, Yang Ju, Guanbin Song","doi":"10.20892/j.issn.2095-3941.2023.0229","DOIUrl":"10.20892/j.issn.2095-3941.2023.0229","url":null,"abstract":"Over the past 2 decades, cancer stem cells (CSCs) have been identified as the root cause of cancer occurrence, progression, chemoradioresistance, recurrence, and metastasis. Targeting CSCs is a novel therapeutic strategy for cancer management and treatment. Liver cancer (LC) is a malignant disease that can endanger human health. Studies are increasingly suggesting that changes in the liver mechanical microenvironment are a primary driver triggering the occurrence and development of liver cancer. In this review, we summarize current understanding of the roles of the liver mechano-microenvironment and liver cancer stem cells (LCSCs) in liver cancer progression. We also discuss the relationship between the mechanical heterogeneity of liver cancer tissues and LCSC recruitment and metastasis. Finally, we highlight potential mechanosensitive molecules in LCSCs and mechanotherapy in liver cancer. Understanding the roles and regulatory mechanisms of the mechano-microenvironment and LCSCs may provide fundamental insights into liver cancer progression and aid in further development of novel therapeutic strategies.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138447222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innate IgM antibodies to mannose in patients with gastric cancer. 胃癌患者抗甘露糖的先天性IgM抗体。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2023-11-17 DOI: 10.20892/j.issn.2095-3941.2023.0156

Maxim Petrovich Nikulin, Nadezhda Vladimirovna Shilova, Alexander Dmitrievich Lipatnikov, Ivan Sokratovich Stilidi, Alexandra Vladimirovna Semyanikhina, Nikolai Vladimirovich Bovin, Nikolai Nikolaevich Tupitsyn

引用次数: 0

Using triple radio-immunotherapy to overcome cancer immunotherapy resistance. 利用三联放射免疫疗法克服癌症免疫治疗耐药性。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2023-11-16 DOI: 10.20892/j.issn.2095-3941.2023.0268

Zengfu Zhang, Xiaodong Zhang, Dawei Chen

引用次数: 0

Bacterial therapy: a promising strategy for cancer immunotherapy. 细菌疗法:一种很有前途的癌症免疫治疗策略。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2023-11-14 DOI: 10.20892/j.issn.2095-3941.2023.0292

Yinsong Wang

引用次数: 0

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors. 用于实体瘤治疗的药物再利用：专注于免疫检查点抑制剂。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2023-11-06 DOI: 10.20892/j.issn.2095-3941.2023.0281

Qingxu Liu, Long Li, Wan Qin, Tengfei Chao

{"title":"Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors.","authors":"Qingxu Liu, Long Li, Wan Qin, Tengfei Chao","doi":"10.20892/j.issn.2095-3941.2023.0281","DOIUrl":"10.20892/j.issn.2095-3941.2023.0281","url":null,"abstract":"Cancer remains a significant global health challenge with limited treatment options beyond systemic therapies, such as chemotherapy, radiotherapy, and molecular targeted therapy. Immunotherapy has emerged as a promising therapeutic modality but the efficacy has plateaued, which therefore provides limited benefits to patients with cancer. Identification of more effective approaches to improve patient outcomes and extend survival are urgently needed. Drug repurposing has emerged as an attractive strategy for drug development and has recently garnered considerable interest. This review comprehensively analyses the efficacy of various repurposed drugs, such as transforming growth factor-beta (TGF-β) inhibitors, metformin, receptor activator of nuclear factor-κB ligand (RANKL) inhibitors, granulocyte macrophage colony-stimulating factor (GM-CSF), thymosin α1 (Tα1), aspirin, and bisphosphonate, in tumorigenesis with a specific focus on their impact on tumor immunology and immunotherapy. Additionally, we present a concise overview of the current preclinical and clinical studies investigating the potential therapeutic synergies achieved by combining these agents with immune checkpoint inhibitors.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71478437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reciprocal activation of antigen-presenting cells and CAR T cells triggers a widespread endogenous anti-tumor immune response through sustained high-level IFNγ production. 抗原呈递细胞和CAR T细胞的相互激活通过持续的高水平IFNγ产生触发广泛的内源性抗肿瘤免疫反应。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2023-11-06 DOI: 10.20892/j.issn.2095-3941.2023.0324

Yelei Guo, Chuan Tong, Zhiqiang Wu, Yuting Lu, Yao Wang, Weidong Han

引用次数: 0

TNFSF15 facilitates the differentiation of CD11b⁺ myeloid cells into vascular pericytes in tumors. TNFSF15促进肿瘤中CD11b+髓系细胞分化为血管周细胞。

IF 5.5 2区医学

Cancer Biology & Medicine Pub Date : 2023-11-02 DOI: 10.20892/j.issn.2095-3941.2023.0245

Xiangxiang Gu, Yipan Zhu, Cancan Zhao, Yixin Cao, Jingying Wang, Qiangzhe Zhang, Luyuan Li

{"title":"TNFSF15 facilitates the differentiation of CD11b+ myeloid cells into vascular pericytes in tumors.","authors":"Xiangxiang Gu, Yipan Zhu, Cancan Zhao, Yixin Cao, Jingying Wang, Qiangzhe Zhang, Luyuan Li","doi":"10.20892/j.issn.2095-3941.2023.0245","DOIUrl":"10.20892/j.issn.2095-3941.2023.0245","url":null,"abstract":"Objective: Immature vasculature lacking pericyte coverage substantially contributes to tumor growth, drug resistance, and cancer cell dissemination. We previously demonstrated that tumor necrosis factor superfamily 15 (TNFSF15) is a cytokine with important roles in modulating hematopoiesis and vascular homeostasis. The main purpose of this study was to explore whether TNFSF15 might promote freshly isolated myeloid cells to differentiate into CD11b+ cells and further into pericytes.Methods: A model of Lewis lung cancer was established in mice with red fluorescent bone marrow. After TNFSF15 treatment, CD11b+ myeloid cells and vascular pericytes in the tumors, and the co-localization of pericytes and vascular endothelial cells, were assessed. Additionally, CD11b+ cells were isolated from wild-type mice and treated with TNFSF15 to determine the effects on the differentiation of these cells.Results: We observed elevated percentages of bone marrow-derived CD11b+ myeloid cells and vascular pericytes in TNFSF15-treated tumors, and the latter cells co-localized with vascular endothelial cells. TNFSF15 protected against CD11b+ cell apoptosis and facilitated the differentiation of these cells into pericytes by down-regulating Wnt3a-VEGFR1 and up-regulating CD49e-FN signaling pathways.Conclusions: TNFSF15 facilitates the production of CD11b+ cells in the bone marrow and promotes the differentiation of these cells into pericytes, which may stabilize the tumor neovasculature.","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":5.5,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71429607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cohort profile: design and methods of the Chinese colorectal, breast, lung, liver, and stomach cancer screening trial (C-BLAST). 队列概况：中国结直肠癌、乳腺癌、肺癌、肝癌和胃癌筛查试验（C-BLAST）的设计和方法。

2区医学

Cancer Biology & Medicine Pub Date : 2023-10-27 DOI: 10.20892/j.issn.2095-3941.2023.0278

Yubei Huang, Zhangyan Lyu, Yu Zhang, Xiaomin Liu, Yacong Zhang, Ya Liu, Chao Sheng, Hongyuan Duan, Zeyu Fan, Chenyang Li, Xiao Lin, Zhuowei Feng, Lu Zheng, Zhaoxiang Ye, Hong Lu, Ying Zhu, Dejun Zhou, Xi Wei, Li Ren, Bin Meng, Fangfang Song, Fengju Song, Kexin Chen

引用次数: 0

Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer. dMMR/MSI-H结直肠癌免疫治疗的机遇和挑战。

2区医学

Cancer Biology & Medicine Pub Date : 2023-10-20 DOI: 10.20892/j.issn.2095-3941.2023.0240

Qi Zhang, Jian Li, Lin Shen, Yongsheng Li, Xicheng Wang

{"title":"Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer.","authors":"Qi Zhang, Jian Li, Lin Shen, Yongsheng Li, Xicheng Wang","doi":"10.20892/j.issn.2095-3941.2023.0240","DOIUrl":"10.20892/j.issn.2095-3941.2023.0240","url":null,"abstract":"Colorectal cancer (CRC) with mismatch-repair deficiency (dMMR) is a distinct molecular subgroup of tumors that is characterized by a diminished capacity to correct base-pair mismatches in DNA, which leads to changes in microsatellite sequences and results in high microsatellite instability (MSI-H) accompanied by hypermutation 1 . The incidence of dMMR/ MSI-H in patients with CRC has been reported to be 15% (12% with sporadic disease and 3% with Lynch syndrome). The incidence varies by stage, with 20% in stage II, 10%–15% in stage III, and 3%–5% in stage IV 2 . Despite the presence of numerous neoantigens that promote tumor-infiltrating lymphocytes in the microenvironment, dMMR/MSI-H CRC also exhibits significantly increased expression of immune checkpoints, such as PD-1 and CTLA-4 3 . Immune checkpoint inhibitor (ICI) therapy has been shown to have high sensitivity for dMMR/MSI-H metastatic CRC (mCRC). Additionally, promising results have been obtained in several trials involving locally advanced dMMR/MSI-H CRC. As the search of ICIs for dMMR/MSI-H CRC treatment continues, clinical practice faces numerous opportunities and challenges ( Figure 1 ).","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49694313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in the systemic treatment of gastrointestinal stromal tumors. 胃肠道间质瘤系统治疗的最新进展。

2区医学

Cancer Biology & Medicine Pub Date : 2023-10-20 DOI: 10.20892/j.issn.2095-3941.2023.0302

Robin L Jones, Marin Golčić

引用次数: 0